Australia National Pathology Standards (First Edition 2027)
Standard 4: Pathology laboratory supervision – Australia National Pathology Standards (First Edition 2027)

Australia National Pathology Standards (First Edition 2027) 4.05: GY and B laboratories: undertake a documented, ongoing risk assessment of the adequacy of onsite supervision covering test volume, complexity and acuity, workforce composition and capability, error and incident data and feedback and complaints, and implement onsite supervision commensurate with the risk where patient safety, quality or service integrity may be compromised

What does 4.05 require?

Whether onsite supervision at a GY or B site is enough is a documented judgement that is kept under review. The assessment weighs the volume of testing, its complexity and acuity, who is on the staff and what they can do, the error and incident record, and feedback and complaints. If it shows that patient safety, quality or the integrity of the service could suffer, onsite supervision is strengthened in proportion to the risk.

Maintained by Gerard Blokdyk

What else in your programme already covers this

This control maps to 1 controls across 1 other frameworks. If you already hold one of them, the evidence you collected for it is the starting point here rather than new work.

ISO 15189:2022 - Medical Laboratories Requirements for Quality and Competence · 1 control

  • 5.6 5.6 Risk management

Every mapping shown was judged rather than inferred from wording similarity, and the ones that failed review are published too. See the coverage reports and what was rejected.

Other controls in Standard 4: Pathology laboratory supervision – Australia National Pathology Standards (First Edition 2027)

Query this from an agent

The graph holds this control, the 1 it maps to, and the evidence behind each claim, over MCP and REST.

MCP endpointAll Australia National Pathology Standards (First Edition 2027) controls